Birch Pollen Allergy Clinical Trial
Official title:
A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, Bet v 1
| Verified date | March 2013 |
| Source | Allergopharma GmbH & Co. KG |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Germany: Paul-Ehrlich-Institut |
| Study type | Interventional |
Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis
| Status | Completed |
| Enrollment | 0 |
| Est. completion date | June 2009 |
| Est. primary completion date | June 2006 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 60 Years |
| Eligibility |
Inclusion Criteria: - Positive Skin Prick Test reaction to birch pollen - Positive RAST result to birch pollen - Positive Provocation Test result to birch pollen Exclusion Criteria: - Serious chronic diseases - Other perennial allergies |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Germany | Allergopharma GmbH & Co. KG | Reinbek |
| Lead Sponsor | Collaborator |
|---|---|
| Allergopharma GmbH & Co. KG |
Germany,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06037148 -
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
|
Phase 1 | |
| Completed |
NCT04912076 -
S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen
|
Phase 1 | |
| Recruiting |
NCT05346718 -
Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis
|
N/A | |
| Completed |
NCT01137357 -
Probiotics for Reduction Of Markers In Subjects With Allergy
|
N/A | |
| Active, not recruiting |
NCT05668390 -
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma
|
Phase 3 | |
| Not yet recruiting |
NCT02146300 -
Effect of the Nasal Provocation on the Breathing Style
|
N/A | |
| Completed |
NCT01449786 -
Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy
|
Phase 2 | |
| Completed |
NCT03969849 -
Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants
|
Phase 1 | |
| Completed |
NCT04435678 -
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
|
N/A | |
| Completed |
NCT01628484 -
Physiological Study to Determine the Allergic Skin Activity After Different Skin Preparation
|
Phase 1 | |
| Completed |
NCT00932607 -
SUBLIVAC® Birch PROBE Study
|
Phase 2 | |
| Completed |
NCT00266526 -
Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV
|
Phase 2 | |
| Completed |
NCT02074930 -
Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure
|
N/A | |
| Completed |
NCT02143583 -
Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment
|
Phase 2 | |
| Completed |
NCT04266028 -
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
|
Phase 1 | |
| Completed |
NCT01675791 -
A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet
|
Phase 2 |